Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy and Sandoz, is a world leader providing healthcare solutions that address the evolving needs of patients and societies.
Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in all these areas.
Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 127,000 full-time-equivalent associates globally.
On March 7th, 1996, Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.
Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis, committed to discovering innovative medicines that treat disease and improve human health. NIBR takes a unique approach to pharmaceutical research. At the earliest stages, research priorities are determined by patient need and disease understanding.